SINE (selective inhibitor of nuclear export) - Translational science in a new class of anti-cancer agents

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Gerecitano, John ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEAR PROTEIN; SELECTIVE INHIBITOR OF NUCLEAR EXPORT; SELINEXOR; UNCLASSIFIED DRUG; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL NUCLEUS; CYTOPLASM; HUMAN; NONHUMAN; REVIEW; TRANSLATIONAL RESEARCH; ACTIVE TRANSPORT; ANIMAL; DRUG EFFECTS; METABOLISM;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; HYDRAZINES; KARYOPHERINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSLATIONAL MEDICAL RESEARCH; TRIAZOLES;

EID: 84907920216     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0067-3     Document Type: Review

References (20)

1. Clinical translation of nuclear export inhibitors in cancer. WT Senapedis, E Baloglu, Y Landesman, Semin Cancer Biol 2014 27C 74 86 10.1016/j.semcancer.2014.04.005
2. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. A Noske, W Weichert, S Niesporek, A Roske, AC Buckendahl, I Koch, J Sehouli, M Dietel, C Denkert, Cancer 2008 112 8 1733 1743 10.1002/cncr.23354 18306389
3. Prognostic value of CRM1 in pancreas cancer. WY Huang, L Yue, WS Qiu, LW Wang, XH Zhou, YJ Sun, Clin Invest Med 2009 32 6 315 20003838
4. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. PJ van der Watt, CP Maske, DT Hendricks, MI Parker, L Denny, D Govender, MJ Birrer, VD Leaner, Int J Cancer 2009 124 8 1829 1840 10.1002/ijc.24146 19117056
5. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. A Shen, Y Wang, Y Zhao, L Zou, L Sun, C Cheng, Neurosurgery 2009 65 1 153 159 10.1227/01.NEU.0000348550.47441.4B 19574837
6. The expression of CRM1 is associated with prognosis in human osteosarcoma. Y Yao, Y Dong, F Lin, H Zhao, Z Shen, P Chen, YJ Sun, LN Tang, SE Zheng, Oncol Rep 2009 21 1 229 235 19082467
7. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. K Kojima, SM Kornblau, V Ruvolo, A Dilip, S Duvvuri, RE Davis, M Zhang, Z Wang, KR Coombes, N Zhang, YH Qui, JK Burks, H Kanatarjian, S Shacham, M Kauffman, M Andreeff, YH Qui, JK Burks, H Kanatarjian, S Shacham, M Kauffman, M Andreeff, Blood 2013 121 20 4166 4174 10.1182/blood-2012-08-447581 23564911
8. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. K Zhang, M Wang, AT Tamayo, S Shacham, M Kauffman, J Lee, L Zhang, Z Ou, C Li, L Sun, RJ Ford, LV Pham, Exp Hematol 2013 41 1 67 78 10.1016/j.exphem.2012.09.002 22986101
9. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. J Schmidt, E Braggio, KM Kortuem, JB Egan, YX Zhu, CS Xin, RE Tiedemann, SE Palmer, VM Garbitt, D McCauley, M Kauffman, S Shacham, M Chesi, PL Bergsagel, AK Stewart, Leukemia 2013 27 12 2357 2365 10.1038/leu.2013.172 23752175
10. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. H Inoue, M Kauffman, S Shacham, Y Landesman, J Yang, CP Evans, RH Weiss, J Urol 2013 189 6 2317 2326 10.1016/j.juro.2012.10.018 23079374
11. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. R Lapalombella, Q Sun, K Williams, L Tangeman, S Jha, Y Zhong, V Goettl, E Mahoney, C Berglund, S Gupta, A Farmer, R Mani, AJ Johnson, D Lucas, X Mo, D Daeleman, V Sandanayaka, S Shechter, D McCauley, S Shacham, M Kauffman, YM Chook, JC Byrd, Blood 2012 120 23 4621 4634 10.1182/blood-2012-05-429506 23034282
12. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. G Pathria, C Wagner, SN Wagner, J Invest Dermatol 2012 132 12 2780 2790 10.1038/jid.2012.233 22832492
13. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias. CJ Walker, JJ Oaks, R Santhanam, P Neviani, JG Harb, G Ferenchak, JJ Ellis, Y Landesman, AK Eisfeld, NY Gabrail, CL Smith, MA Caligiuri, P Hokland, DC Roy, A Reid, D Milojkovic, JM Goldman, J Apperley, R Garzon, G Marcucci, S Shacham, MG Kauffman, D Perrotti, Blood 2013 122 17 3034 3044 10.1182/blood-2013-04-495374 23970380
14. Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial Ofa first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory Non Hodgkin's lymphoma (NHL) and chronic lymphocytic L. J Kuruvilla, M Gutierrez, BD Shah, NY Gabrail, P de Nully Brown, RM Stone, R Garzon, M Savona, DS Siegel, R Baz, M Mau-Sorensen, MS Davids, JC Byrd, S Shacham, T Rashal, CYF Yau, D McCauley, J-R Saint-Martin, J McCartney, Y Landesman, B Klebanov, G Pond, AM Oza, M Kauffman, MR Mirza, Blood 2013 122 90
15. Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S: Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget 2014, 13. in press.
16. XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). Gravina, M Tortoreto, A Mancini, A Addis, E Di Cesare, A Lenzi, Y Landesman, D McCauley, M Kauffman, S Shacham, N Zaffaroni, C Festuccia, J Hematol Oncol 2014 7 46 10.1186/1756-8722-7-46 25284315
17. Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed/Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM). CI Chen, M Gutierrez, PN Brown, N Gabrail, R Baz, DE Reece, M Savona, S Trudel, DS Siegel, M Mau-Sorensen, J Kuruvilla, JC Byrd, S Shacham, T Rashal, CYF Yau, D McCauley, JR Saint-Martin, J McCartney, Y Landesman, B Klebanov, G Pond, A Oza, M Kauffman, MR Mirza, Blood 2013 122 1942
18. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). M Savona, R Garzon, PN Brown, K Yee, JE Lancet, M Gutierrez, N Gabrail, M Mau-Sorensen, R Baz, JC Byrd, J Kuruvilla, DS Siegel, S Shacham, T Rashal, CYF Yau, D McCauley, JR Saint-Martin, J McCartney, Y Landesman, B Klebanov, G Pond, AM Oza, M Kauffman, MR Mirza, RM Stone, Blood 2013 122 1440
19. A first-in-class, first-in-human Phase I trial of KPT-330 (Selinexor), a Selective Inhibitor of Nuclear Export (SINE) in patients (pts) with advanced solid tumors. M Mau-Sorensen, A Razak, AF Shields, NY Gabrail, JF Gerecitano, S Shacham, UN Lassen, T Rashal, J Cooksey, Y Landesman, G Pond, AM Oza, M Kauffman, LL Siu, PL Bedard, H Mahaseth, MR Mirza, A Mahipal, J Clin Oncol 2014 32 5s suppl; abstr 2537 10.1200/JCO.2013.49.4757
20. Phase I trial of elactocin. ES Newlands, GJ Rustin, MH Brampton, Br J Cancer 1996 74 4 648 649 10.1038/bjc.1996.415 8761384